Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA

M. Rinaldi, A. L. Catapano, P. Parrella, S. A. Ciafrè, E. Signori, D. Seripa, P. Uboldi, R. Antonini, G. Ricci, M. G. Farace, V. M. Fazio

Research output: Contribution to journalArticle

Abstract

We report on systemic delivery and long-term biological effects of apolipoprotein E (apoE) obtained by intramuscular (i.m.) plasmid DNA injection. ApoE plays an important role in lipoprotein catabolism and apoE knock-out mice develop severe hypercholesterolemia and diffuse atherosclerosis. We have injected apoE-deficient mice with 80 μg of a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA under the control of the CMV promoter-enhancer in both posterior legs. Local expression of the transgene was demonstrated throughout 16 weeks. Human apoE3 recombinant protein reached 0.6 ng/ml serum level. After i.m. injection of pCMV-E3 expression vector the mean serum cholesterol concentrations decreased from 439±57 mg/dl to 253±99 mg/dl (P <0.05) 2 weeks after injection and persisted at a significantly reduced level throughout the 16 weeks observation period (P <0.005). Serum cholesterol was unaffected and reached an absolute level of 636±67 mg/dl in control groups. Finally, injection of pCMV-E3 into apoE-deficient mice resulted in a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol. These results demonstrate that severe hypercholesterolemia in apoE-deficient mice can be effectively reversed by i.m. DNA injection, and indicate that this approach could represent a useful tool to correct several hyperlipidemic conditions resulting in atherosclerosis.

Original languageEnglish
Pages (from-to)1795-1801
Number of pages7
JournalGene Therapy
Volume7
Issue number21
Publication statusPublished - 2000

Fingerprint

Intramuscular Injections
Apolipoproteins E
Hypercholesterolemia
Plasmids
DNA
Apolipoprotein E3
Cholesterol
Injections
Lipoproteins
Atherosclerosis
Therapeutics
Serum
VLDL Cholesterol
Transgenes
Recombinant Proteins
Knockout Mice
LDL Cholesterol
HDL Cholesterol
Leg
Complementary DNA

Keywords

  • Apolipoprotein-E
  • Hypercholesterolemia
  • Intramuscular injection
  • Long-term gene therapy
  • Plasmid DNA

ASJC Scopus subject areas

  • Genetics

Cite this

Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. / Rinaldi, M.; Catapano, A. L.; Parrella, P.; Ciafrè, S. A.; Signori, E.; Seripa, D.; Uboldi, P.; Antonini, R.; Ricci, G.; Farace, M. G.; Fazio, V. M.

In: Gene Therapy, Vol. 7, No. 21, 2000, p. 1795-1801.

Research output: Contribution to journalArticle

Rinaldi, M, Catapano, AL, Parrella, P, Ciafrè, SA, Signori, E, Seripa, D, Uboldi, P, Antonini, R, Ricci, G, Farace, MG & Fazio, VM 2000, 'Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA', Gene Therapy, vol. 7, no. 21, pp. 1795-1801.
Rinaldi, M. ; Catapano, A. L. ; Parrella, P. ; Ciafrè, S. A. ; Signori, E. ; Seripa, D. ; Uboldi, P. ; Antonini, R. ; Ricci, G. ; Farace, M. G. ; Fazio, V. M. / Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. In: Gene Therapy. 2000 ; Vol. 7, No. 21. pp. 1795-1801.
@article{1a8bb105b4324776b0f04f5ce2c158e6,
title = "Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA",
abstract = "We report on systemic delivery and long-term biological effects of apolipoprotein E (apoE) obtained by intramuscular (i.m.) plasmid DNA injection. ApoE plays an important role in lipoprotein catabolism and apoE knock-out mice develop severe hypercholesterolemia and diffuse atherosclerosis. We have injected apoE-deficient mice with 80 μg of a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA under the control of the CMV promoter-enhancer in both posterior legs. Local expression of the transgene was demonstrated throughout 16 weeks. Human apoE3 recombinant protein reached 0.6 ng/ml serum level. After i.m. injection of pCMV-E3 expression vector the mean serum cholesterol concentrations decreased from 439±57 mg/dl to 253±99 mg/dl (P <0.05) 2 weeks after injection and persisted at a significantly reduced level throughout the 16 weeks observation period (P <0.005). Serum cholesterol was unaffected and reached an absolute level of 636±67 mg/dl in control groups. Finally, injection of pCMV-E3 into apoE-deficient mice resulted in a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol. These results demonstrate that severe hypercholesterolemia in apoE-deficient mice can be effectively reversed by i.m. DNA injection, and indicate that this approach could represent a useful tool to correct several hyperlipidemic conditions resulting in atherosclerosis.",
keywords = "Apolipoprotein-E, Hypercholesterolemia, Intramuscular injection, Long-term gene therapy, Plasmid DNA",
author = "M. Rinaldi and Catapano, {A. L.} and P. Parrella and Ciafr{\`e}, {S. A.} and E. Signori and D. Seripa and P. Uboldi and R. Antonini and G. Ricci and Farace, {M. G.} and Fazio, {V. M.}",
year = "2000",
language = "English",
volume = "7",
pages = "1795--1801",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "21",

}

TY - JOUR

T1 - Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA

AU - Rinaldi, M.

AU - Catapano, A. L.

AU - Parrella, P.

AU - Ciafrè, S. A.

AU - Signori, E.

AU - Seripa, D.

AU - Uboldi, P.

AU - Antonini, R.

AU - Ricci, G.

AU - Farace, M. G.

AU - Fazio, V. M.

PY - 2000

Y1 - 2000

N2 - We report on systemic delivery and long-term biological effects of apolipoprotein E (apoE) obtained by intramuscular (i.m.) plasmid DNA injection. ApoE plays an important role in lipoprotein catabolism and apoE knock-out mice develop severe hypercholesterolemia and diffuse atherosclerosis. We have injected apoE-deficient mice with 80 μg of a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA under the control of the CMV promoter-enhancer in both posterior legs. Local expression of the transgene was demonstrated throughout 16 weeks. Human apoE3 recombinant protein reached 0.6 ng/ml serum level. After i.m. injection of pCMV-E3 expression vector the mean serum cholesterol concentrations decreased from 439±57 mg/dl to 253±99 mg/dl (P <0.05) 2 weeks after injection and persisted at a significantly reduced level throughout the 16 weeks observation period (P <0.005). Serum cholesterol was unaffected and reached an absolute level of 636±67 mg/dl in control groups. Finally, injection of pCMV-E3 into apoE-deficient mice resulted in a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol. These results demonstrate that severe hypercholesterolemia in apoE-deficient mice can be effectively reversed by i.m. DNA injection, and indicate that this approach could represent a useful tool to correct several hyperlipidemic conditions resulting in atherosclerosis.

AB - We report on systemic delivery and long-term biological effects of apolipoprotein E (apoE) obtained by intramuscular (i.m.) plasmid DNA injection. ApoE plays an important role in lipoprotein catabolism and apoE knock-out mice develop severe hypercholesterolemia and diffuse atherosclerosis. We have injected apoE-deficient mice with 80 μg of a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA under the control of the CMV promoter-enhancer in both posterior legs. Local expression of the transgene was demonstrated throughout 16 weeks. Human apoE3 recombinant protein reached 0.6 ng/ml serum level. After i.m. injection of pCMV-E3 expression vector the mean serum cholesterol concentrations decreased from 439±57 mg/dl to 253±99 mg/dl (P <0.05) 2 weeks after injection and persisted at a significantly reduced level throughout the 16 weeks observation period (P <0.005). Serum cholesterol was unaffected and reached an absolute level of 636±67 mg/dl in control groups. Finally, injection of pCMV-E3 into apoE-deficient mice resulted in a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol. These results demonstrate that severe hypercholesterolemia in apoE-deficient mice can be effectively reversed by i.m. DNA injection, and indicate that this approach could represent a useful tool to correct several hyperlipidemic conditions resulting in atherosclerosis.

KW - Apolipoprotein-E

KW - Hypercholesterolemia

KW - Intramuscular injection

KW - Long-term gene therapy

KW - Plasmid DNA

UR - http://www.scopus.com/inward/record.url?scp=0033721157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033721157&partnerID=8YFLogxK

M3 - Article

C2 - 11110410

AN - SCOPUS:0033721157

VL - 7

SP - 1795

EP - 1801

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 21

ER -